Growth Metrics

Aptevo Therapeutics (APVO) Operating Margin (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Operating Margin for 8 consecutive years, with 180.19% as the latest value for Q1 2022.

  • Quarterly Operating Margin rose 10432.0% to 180.19% in Q1 2022 from the year-ago period, while the trailing twelve-month figure was 919.75% through Dec 2022, down 74565.0% year-over-year, with the annual reading at 919.75% for FY2022, 74565.0% down from the prior year.
  • Operating Margin hit 180.19% in Q1 2022 for Aptevo Therapeutics, down from 110.23% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 87.88% in Q4 2019 to a low of 1439.11% in Q2 2020.
  • Historically, Operating Margin has averaged 289.41% across 5 years, with a median of 182.3% in 2018.
  • Biggest five-year swings in Operating Margin: tumbled -126389bps in 2020 and later surged 125512bps in 2021.
  • Year by year, Operating Margin stood at 208.22% in 2018, then soared by 58bps to 87.88% in 2019, then crashed by -227bps to 287.36% in 2020, then soared by 62bps to 110.23% in 2021, then plummeted by -63bps to 180.19% in 2022.
  • Business Quant data shows Operating Margin for APVO at 180.19% in Q1 2022, 110.23% in Q4 2021, and 153.42% in Q3 2021.